Drug intelligence / Profile preview

UPR activator (liver)

Development stage: Preclinical
Lead developer: Protego Biopharma
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

Protego Biopharma is developing a small-molecule activator of the Unfolded Protein Response (UPR) pathway for the treatment of various liver diseases. This program is part of the company's broader proteostasis platform, which leverages research from Scripps Research to address protein misfolding disorders. By pharmacologically activating the UPR, the drug is intended to enhance the endoplasmic reticulum's capacity to fold proteins and degrade misfolded aggregates, thereby addressing the underlying cellular stress and pathology associated with hepatic proteinopathies. The program is currently in the lead optimization stage of development.

Other names: UPR Activator (Liver)Unfolded Protein Response activator

Beyond the preview

Go deeper on UPR activator (liver).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UPR activator (liver).

Explore the full profile